| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Epidemiology and Prevention |
Departments of 1 Medicine and 2 Cell and Developmental Biology, Weill Medical College of Cornell University; 3 Strang Cancer Research Laboratory at The Rockefeller University; Departments of 4 Surgery, 5 Pathology, and 6 Medicine, Memorial Sloan-Kettering Cancer Center, New York, New York; and 7 Center for Vascular Biology, Department of Cell Biology, University of Connecticut Health Center, Farmington, Connecticut
Requests for reprints: Kotha Subbaramaiah, New York Presbyterian Hospital-Cornell, 525 East 68th Street, Room F-203A, New York, NY 10021. Phone: 212-746-4402; Fax: 212-746-4885; E-mail: ksubba{at}med.cornell.edu or Andrew J. Dannenberg, New York Presbyterian Hospital-Cornell, 525 East 68th Street, Room F-206, New York, NY 10021. Phone: 212-746-4403; Fax: 212-746-4885; E-mail: ajdannen{at}med.cornell.edu.
Cytochrome P450 aromatase (aromatase), a product of the CYP19 gene, catalyzes the synthesis of estrogens from androgens. Given the significance of estrogen synthesis in hormone-dependent breast carcinogenesis, it is important to elucidate the mechanisms that regulate CYP19 expression. The main objective of this study was to define the interrelationship between HER-2/neu, cyclooxygenase-2 (COX-2), and aromatase in mammary tissue. Mammary aromatase activity and prostaglandin E2 (PGE2) levels were increased in mice with mammary-targeted expression of a COX-2 transgene. In vitro, overexpressing COX-2 caused both increased PGE2 production and aromatase activity, effects that were suppressed by celecoxib, a selective COX-2 inhibitor. Previously, we found that overexpression of HER-2/neu was associated with increased levels of COX-2 in human breast cancers. Here, we show that overexpression of HER-2/neu is also associated with increased aromatase activity. These results suggested the possibility that COX-2 was the functional intermediate linking HER-2/neu and aromatase. Consistent with this idea, COX-2 deficiency led to a gene dose-dependent reduction in mammary aromatase activity in a HER-2/neu transgenic mouse model. Complementary in vitro studies showed that HER-2/neu–mediated induction of PGE2 synthesis and aromatase activity were suppressed by inhibiting COX-2. Collectively, our data indicate that COX-2 is the functional intermediate linking HER-2/neu and aromatase and suggest that inhibitors of PGE2 synthesis will suppress estrogen biosynthesis in breast tissue. (Cancer Res 2006; 66(10): 5504-11)
This article has been cited by other articles:
|
|
 |
|
  L. R. Howe and S. M. Lippman Modulation of Breast Cancer Risk by Nonsteroidal Anti-inflammatory Drugs J Natl Cancer Inst, October 15, 2008; 100(20): 1420 - 1423. [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Hardy, B. A. Janowski, C.-C. Chen, and C. R. Mendelson Progesterone Receptor Inhibits Aromatase and Inflammatory Response Pathways in Breast Cancer Cells via Ligand-Dependent and Ligand-Independent Mechanisms Mol. Endocrinol., August 1, 2008; 22(8): 1812 - 1824. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Brown, K. Subbaramaiah, A. P. Salmon, R. Baker, R. A. Newman, P. Yang, X. K. Zhou, R. P. Bissonnette, A. J. Dannenberg, and L. R. Howe Combination Chemoprevention of HER2/neu-Induced Breast Cancer Using a Cyclooxygenase-2 Inhibitor and a Retinoid X Receptor-Selective Retinoid Cancer Prevention Research, August 1, 2008; 1(3): 208 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Rajhans, H. B. Nair, S. S. Nair, V. Cortez, K. Ikuko, N. B. Kirma, D. Zhou, A. E. Holden, D. W Brann, S. Chen, et al. Modulation of in Situ Estrogen Synthesis by Proline-, Glutamic Acid-, and Leucine-Rich Protein-1: Potential Estrogen Receptor Autocrine Signaling Loop in Breast Cancer Cells Mol. Endocrinol., March 1, 2008; 22(3): 649 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Subbaramaiah, C. Hudis, S.-H. Chang, T. Hla, and A. J. Dannenberg EP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells: EVIDENCE OF A BRCA1 AND p300 EXCHANGE J. Biol. Chem., February 8, 2008; 283(6): 3433 - 3444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Mah, D. B. Seligson, A. Li, D. C. Marquez, I. I. Wistuba, Y. Elshimali, M. C. Fishbein, D. Chia, R. J. Pietras, and L. Goodglick Aromatase Expression Predicts Survival in Women with Early-Stage Non Small Cell Lung Cancer Cancer Res., November 1, 2007; 67(21): 10484 - 10490. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. R. Yang, R. M. Pfeiffer, M. Garcia-Closas, D. L. Rimm, J. Lissowska, L. A. Brinton, B. Peplonska, S. M. Hewitt, R. W. Cartun, D. Mandich, et al. Hormonal Markers in Breast Cancer: Coexpression, Relationship with Pathologic Characteristics, and Risk Factor Associations in a Population-Based Study Cancer Res., November 1, 2007; 67(21): 10608 - 10617. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R J. Barnard Prostate cancer prevention by nutritional means to alleviate metabolic syndrome Am. J. Clinical Nutrition, September 1, 2007; 86(3): 889S - 893S. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Pietras and D. C. Marquez-Garban Membrane-Associated Estrogen Receptor Signaling Pathways in Human Cancers Clin. Cancer Res., August 15, 2007; 13(16): 4672 - 4676. [Full Text] [PDF]
|
|
|
|
|
|
F. Meric-Bernstam and M.-C. Hung Advances in targeting human epidermal growth factor receptor-2 signaling for cancer therapy. Clin. Cancer Res., November 1, 2006; 12(21): 6326 - 6330. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
